RATIO-SALBUTAMOL SOLUTION
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
12-10-2016
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
SALBUTAMOL (SALBUTAMOL SULFATE)
Tillgänglig från:
TEVA CANADA LIMITED
ATC-kod:
R03AC02
INN (International namn):
SALBUTAMOL
Dos:
1MG
Läkemedelsform:
SOLUTION
Sammansättning:
SALBUTAMOL (SALBUTAMOL SULFATE) 1MG
Administreringssätt:
INHALATION
Enheter i paketet:
10ML
Receptbelagda typ:
Prescription
Terapiområde:
SELECTIVE BETA 2-ADRENERGIC AGONISTS
Produktsammanfattning:
Active ingredient group (AIG) number: 0108887007; AHFS:
Bemyndigande status:
CANCELLED POST MARKET
Tillstånd datum:
2018-05-18
Produktens egenskaper
PRODUCT MONOGRAPH
RATIO-SALBUTAMOL
salbutamol sulphate respirator solution
1 mg/mL
Bronchodilator
(beta
2
-adrenergic stimulant)
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
Canada, M1B 2K9
Control: 166142
DATE OF PREPARATION:
JULY 24, 2013
2/32
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................................................
3
SUMMARY PRODUCT INFORMATION
.............................................................................................................
3
INDICATIONS AND CLINICAL USE
....................................................................................................................
3
CONTRAINDICATIONS
.........................................................................................................................................
3
WARNINGS AND PRECAUTIONS
......................................................................................................................
3
ADVERSE REACTIONS
........................................................................................................................................
7
DRUG INTERACTIONS
.........................................................................................................................................
8
DOSAGE AND ADMINISTRATION
....................................................................................................................
10
OVERDOSAGE
.....................................................................................................................................................
12
ACTION AND CLINICAL PHARMACOLOGY
...................................................................................................
12
STORAGE AND STABILITY
...............................................................................................................................
13
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................................................
14
PART II: S
Läs hela dokumentet
